{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:16:51Z","timestamp":1761895011964},"reference-count":27,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Lymphoma and Myeloma"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.3816\/clm.2009.n.087","type":"journal-article","created":{"date-parts":[[2010,1,6]],"date-time":"2010-01-06T02:02:24Z","timestamp":1262743344000},"page":"443-448","source":"Crossref","is-referenced-by-count":7,"title":["Favorable Consolidative Effect of High-Dose Melphalan and Total-Body Irradiation Followed by Autologous Peripheral Blood Stem Cell Transplantation After Rituximab-Containing Induction Chemotherapy With In Vivo Purging in Relapsed or Refractory Follicular Lymphoma"],"prefix":"10.3816","volume":"9","author":[{"given":"Harumi","family":"Kato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Taji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michinori","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitoyo","family":"Kagami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Oki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akane","family":"Tsujimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobukazu","family":"Fuwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Kodaira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masao","family":"Seto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhito","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuo","family":"Morishima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CLM.2009.n.087_bib1","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.1986.4.10.1470","article-title":"Follicular lymphoma: prognostic factors for response and survival","volume":"4","author":"Gallagher","year":"1986","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.n.087_bib2","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1200\/JCO.1995.13.1.140","article-title":"Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center","volume":"13","author":"Johnson","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.n.087_bib3","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1200\/JCO.1993.11.4.644","article-title":"Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy","volume":"11","author":"Dana","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.n.087_bib4","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1200\/JCO.2006.09.8327","article-title":"Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up","volume":"25","author":"Rohatiner","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.n.087_bib5","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.bbmt.2007.04.009","article-title":"A 15-year analysis of early and late autologous hematopoietic stem cell transplant in relapsed aggressive, transformed, and nontransformed follicular lymphom","volume":"13","author":"Sabloff","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.3816\/CLM.2009.n.087_bib6","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2003.10.023","article-title":"High-dose therapy improves progressionfree survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial","volume":"21","author":"Schouten","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.n.087_bib7","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1200\/JCO.2000.18.3.527","article-title":"High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: longterm clinical and molecular follow-up","volume":"18","author":"Apostolidis","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.n.087_bib8","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1182\/blood.V94.10.3325.422k13_3325_3333","article-title":"Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma","volume":"94","author":"Freedman","year":"1999","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.087_bib9","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1182\/blood.V81.12.3449.3449","article-title":"Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma","volume":"81","author":"Gribben","year":"1993","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.087_bib10","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1200\/JCO.2004.10.054","article-title":"Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes","volume":"22","author":"Corradini","year":"2004","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"10.3816\/CLM.2009.n.087_bib11","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1007\/s002800051062","article-title":"Phase I\/II trial of cure-oriented high-dose chemoradiotherapy with transplantation of CD34+ peripheral blood stem cells purified by the immunomagnetic bead method for refractory hematological malignancies. Nagoya CD34+ PBSCT Study Group","volume":"40","author":"Ogura","year":"1997","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.3816\/CLM.2009.n.087_bib12","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/BF02982008","article-title":"CD34+-selected autologous peripheral blood stem cell transplantation conditioned with total body irradiation for malignant lymphoma: increased risk of infectious complications","volume":"74","author":"Maeda","year":"2001","journal-title":"Int J Hematol"},{"key":"10.3816\/CLM.2009.n.087_bib13","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1053\/bbmt.2002.v8.pm12064366","article-title":"Infectious complications after autologous CD34-selected peripheral blood stem cell transplantation","volume":"8","author":"Crippa","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.3816\/CLM.2009.n.087_bib14","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1349-7006.2007.00662.x","article-title":"Phase II study of a salvage regimen using cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide, and rituximab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma","volume":"99","author":"Oki","year":"2008","journal-title":"Cancer Sci"},{"key":"10.3816\/CLM.2009.n.087_bib15","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/BF02986620","article-title":"Pilot phase I\/II study of new salvage therapy (CHASE) for refractory or relapsed malignant lymphoma","volume":"77","author":"Ogura","year":"2003","journal-title":"Int J Hematol"},{"key":"10.3816\/CLM.2009.n.087_bib16","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/S1083-8791(00)70028-0","article-title":"Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma","volume":"6","author":"Flinn","year":"2000","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.3816\/CLM.2009.n.087_bib17","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.n.087_bib18","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1080\/07357900701809068","article-title":"Profound hypogammaglobulinaemia 7 years after treatment for indolent lymphoma","volume":"26","author":"Walker","year":"2008","journal-title":"Cancer Invest"},{"key":"10.3816\/CLM.2009.n.087_bib19","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1097\/TP.0b013e318188ac0c","article-title":"Prolonged agammaglobulinaemia despite unaltered B-cell lymphopoiesis after peritransplant-rituximab administration in a child","volume":"86","author":"Gu\u00e9rin","year":"2008","journal-title":"Transplantation"},{"key":"10.3816\/CLM.2009.n.087_bib20","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1182\/blood.V89.2.724","article-title":"Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting","volume":"89","author":"Corradini","year":"1997","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.087_bib21","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1182\/blood.V88.7.2780.bloodjournal8872780","article-title":"High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission","volume":"88","author":"Freedman","year":"1996","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.087_bib22","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1182\/blood-2006-03-013193","volume":"108","author":"Sebban","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.087_bib23","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1182\/blood-2002-04-1261","article-title":"Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study","volume":"101","author":"Metayer","year":"2003","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.087_bib24","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.bbmt.2007.05.012","article-title":"Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission","volume":"13","author":"Brown","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.3816\/CLM.2009.n.087_bib25","doi-asserted-by":"crossref","first-page":"4711","DOI":"10.1200\/JCO.2004.04.020","article-title":"Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up","volume":"22","author":"Czuczman","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.n.087_bib26","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/annonc\/mdh425","article-title":"Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study","volume":"15","author":"Brugger","year":"2004","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2009.n.087_bib27","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","article-title":"Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial","volume":"108","author":"van Oers","year":"2006","journal-title":"Blood"}],"container-title":["Clinical Lymphoma and Myeloma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011700361?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011700361?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T13:43:22Z","timestamp":1711115002000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1557919011700361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["S1557919011700361"],"URL":"https:\/\/doi.org\/10.3816\/clm.2009.n.087","relation":{},"ISSN":["1557-9190"],"issn-type":[{"value":"1557-9190","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}